The role of the microbiome in immune checkpoint inhibitor colitis and hepatitis
- Journal Title
- Best Practice & Research Clinical Gastroenterology
- Publication Type
- Review
- Abstract
- Immune checkpoint inhibitors have revolutionised management for a variety of different types of malignancies. However, gastrointestinal adverse effects, in particular colitis and hepatitis, are relatively common with up to 30 % of patients being affected. The gut microbiome has emerged as a potential contributor to both the effectiveness of immune checkpoint inhibitors and their side effects. This review will attempt to examine the impact the microbiome has on adverse effects as a result of immune checkpoint inhibitors as well as the potential for manipulation of the microbiome as a form of management for immune mediated colitis.
- Publisher
- Elsevier
- Keywords
- Humans; *Chemical and Drug Induced Liver Injury/immunology/microbiology; *Colitis/chemically induced/microbiology/immunology; *Gastrointestinal Microbiome/drug effects/immunology; *Hepatitis/microbiology/immunology; *Immune Checkpoint Inhibitors/adverse effects; Neoplasms/drug therapy/immunology/microbiology; Immune checkpoint colitis; Microbiome
- Department(s)
- Surgical Oncology
- Publisher's Version
- https://doi.org/10.1016/j.bpg.2024.101945
- Open Access at Publisher's Site
https://doi.org/10.1016/j.bpg.2024.101945- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2025-01-09 06:35:12
Last Modified: 2025-01-09 06:41:23